NO20055307D0 - Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer - Google Patents

Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer

Info

Publication number
NO20055307D0
NO20055307D0 NO20055307A NO20055307A NO20055307D0 NO 20055307 D0 NO20055307 D0 NO 20055307D0 NO 20055307 A NO20055307 A NO 20055307A NO 20055307 A NO20055307 A NO 20055307A NO 20055307 D0 NO20055307 D0 NO 20055307D0
Authority
NO
Norway
Prior art keywords
cancer
diseases
treatment
metabolic disorders
isochroman compounds
Prior art date
Application number
NO20055307A
Other languages
English (en)
Other versions
NO20055307L (no
Inventor
Magnus Pfahl
Catherine Tachdjian
Hussien A Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Jianhua Guo
Mohamed Boudjelal
James W Zapf
Qing Chen
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of NO20055307D0 publication Critical patent/NO20055307D0/no
Publication of NO20055307L publication Critical patent/NO20055307L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055307A 2003-04-18 2005-11-10 Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer NO20055307L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46438803P 2003-04-18 2003-04-18
PCT/US2004/012284 WO2004093809A2 (en) 2003-04-18 2004-04-19 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Publications (2)

Publication Number Publication Date
NO20055307D0 true NO20055307D0 (no) 2005-11-10
NO20055307L NO20055307L (no) 2005-12-21

Family

ID=33310879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055307A NO20055307L (no) 2003-04-18 2005-11-10 Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer

Country Status (13)

Country Link
US (1) US20050038098A1 (no)
EP (1) EP1643993A2 (no)
JP (1) JP2006523724A (no)
KR (1) KR20060036896A (no)
CN (1) CN1774246A (no)
AU (1) AU2004232326A1 (no)
BR (1) BRPI0409501A (no)
CA (1) CA2522759A1 (no)
MX (1) MXPA05011242A (no)
NO (1) NO20055307L (no)
RU (1) RU2005135850A (no)
WO (1) WO2004093809A2 (no)
ZA (1) ZA200509355B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7349100A (en) 1999-08-31 2001-03-26 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
CN102329192A (zh) * 2011-09-30 2012-01-25 山东天一化学股份有限公司 溴化苄的合成方法
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
CN105315223B (zh) * 2015-11-06 2017-08-25 河南大学 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
DE3874257T2 (de) * 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
AU660701B2 (en) * 1991-07-22 1995-07-06 Pfizer Inc. Process for the preparation of intermediates in the synthesis of chiral thiazolidine-2,4-dione derivatives
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
HUT74611A (en) * 1994-02-17 1997-01-28 American Home Prod Biphenyl derivatives with phosphodiesterase inhibitor activity and pharmaceutical compns. contg. them
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
US6127415A (en) * 1996-07-08 2000-10-03 Galderma Research & Development, S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
AU7349100A (en) * 1999-08-31 2001-03-26 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
EP1456187A4 (en) * 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases

Also Published As

Publication number Publication date
JP2006523724A (ja) 2006-10-19
ZA200509355B (en) 2007-03-28
BRPI0409501A (pt) 2006-04-18
KR20060036896A (ko) 2006-05-02
AU2004232326A1 (en) 2004-11-04
CN1774246A (zh) 2006-05-17
NO20055307L (no) 2005-12-21
WO2004093809A3 (en) 2005-04-21
MXPA05011242A (es) 2006-07-06
EP1643993A2 (en) 2006-04-12
CA2522759A1 (en) 2004-11-04
WO2004093809A2 (en) 2004-11-04
US20050038098A1 (en) 2005-02-17
RU2005135850A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
NO20050570L (no) Nye forbindelser, preparater og fremgangsmater for behandling av inflammasjonssykdommer og -tilstander
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
CY2014019I1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
ATE408601T1 (de) Fredericamycin-derivate
EP1456187A4 (en) N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
GB0121490D0 (en) Ciompounds
NO20033883D0 (no) Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application